BiomX (NYSEAMERICAN:PHGE) Cut to Hold at HC Wainwright

HC Wainwright downgraded shares of BiomX (NYSEAMERICAN:PHGE) from a buy rating to a hold rating in a research report report published on Monday, MarketBeat Ratings reports.

BiomX Price Performance

Shares of NYSEAMERICAN PHGE opened at $6.24 on Monday. The company has a market capitalization of $9.92 million, a P/E ratio of -0.24 and a beta of 1.68. The company has a 50 day simple moving average of $4.57 and a 200-day simple moving average of $6.52. BiomX has a 1 year low of $1.50 and a 1 year high of $14.71.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings data on Thursday, February 19th. The company reported $6.99 EPS for the quarter. As a group, research analysts expect that BiomX will post -2.77 EPS for the current year.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. bought a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned 5.99% of BiomX as of its most recent SEC filing. 40.57% of the stock is currently owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.